25589620|t|Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
25589620|a|PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy. EXPERIMENTAL DESIGN: DNA from 746 stage II/III rectal patients enrolled in the Southwest Oncology Group (SWOG) S9304 phase III trial was analyzed. Genomic DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue. The polymorphisms were analyzed using direct DNA-sequencing or polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS: GSTP1-Ile105Val (rs1695) was significantly associated with DFS and OS and its effect did not vary by treatment arm. The five-year DFS and OS were 53% and 58%, respectively, for G/G, 66% and 72% for G/A, and 57% and 66% for A/A patients. In arm 2, IL8-251A/A genotype (rs4073) was associated with a lower risk of toxicities (P = 0.04). The VEGFR2 H472Q Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) mucositis (P = 0.04) in arm 2. However, in arm 1, this genotype was associated with a lower risk of PUGIT mucositis (P = 0.004). CONCLUSION: rs1695 may be prognostic in patients with rectal cancer treated with adjuvant CRT. rs4073 and rs1870377 may exhibit different associations with toxicity, according to the 5-FU schedule.
25589620	91	99	Toxicity	DiseaseOrPhenotypicFeature	D064420
25589620	103	116	Rectal Cancer	DiseaseOrPhenotypicFeature	D012004
25589620	117	125	Patients	OrganismTaxon	9606
25589620	139	143	5-FU	ChemicalEntity	D005472
25589620	216	221	GSTP1	GeneOrGeneProduct	2950
25589620	223	227	COX2	GeneOrGeneProduct	4513
25589620	229	233	IL10	GeneOrGeneProduct	3586
25589620	235	239	EGFR	GeneOrGeneProduct	1956
25589620	241	244	EGF	GeneOrGeneProduct	1950
25589620	246	251	FGFR4	GeneOrGeneProduct	2264
25589620	253	258	CCDN1	GeneOrGeneProduct	595
25589620	260	266	VEGFR2	GeneOrGeneProduct	3791
25589620	268	272	VEGF	GeneOrGeneProduct	7422
25589620	274	279	CXCR2	GeneOrGeneProduct	3579
25589620	281	284	IL8	GeneOrGeneProduct	3576
25589620	286	290	MMP3	GeneOrGeneProduct	4314
25589620	292	297	ICAM1	GeneOrGeneProduct	3383
25589620	299	304	ERCC1	GeneOrGeneProduct	2067
25589620	306	311	RAD51	GeneOrGeneProduct	5888
25589620	317	322	XRCC3	GeneOrGeneProduct	7517
25589620	394	402	toxicity	DiseaseOrPhenotypicFeature	D064420
25589620	495	509	5-fluorouracil	ChemicalEntity	D005472
25589620	511	515	5-FU	ChemicalEntity	D005472
25589620	564	578	rectal cancers	DiseaseOrPhenotypicFeature	D012004
25589620	605	609	5-FU	ChemicalEntity	D005472
25589620	622	626	5-FU	ChemicalEntity	D005472
25589620	719	723	5-FU	ChemicalEntity	D005472
25589620	788	792	5-FU	ChemicalEntity	D005472
25589620	866	874	patients	OrganismTaxon	9606
25589620	990	998	formalin	ChemicalEntity	D005557
25589620	1006	1014	paraffin	ChemicalEntity	D010232
25589620	1031	1036	tumor	DiseaseOrPhenotypicFeature	D009369
25589620	1196	1201	GSTP1	GeneOrGeneProduct	2950
25589620	1202	1211	Ile105Val	SequenceVariant	rs1695
25589620	1213	1219	rs1695	SequenceVariant	rs1695
25589620	1423	1431	patients	OrganismTaxon	9606
25589620	1443	1446	IL8	GeneOrGeneProduct	3576
25589620	1446	1453	-251A/A	SequenceVariant	rs4073
25589620	1464	1470	rs4073	SequenceVariant	rs4073
25589620	1508	1518	toxicities	DiseaseOrPhenotypicFeature	D064420
25589620	1535	1541	VEGFR2	GeneOrGeneProduct	3791
25589620	1542	1547	H472Q	SequenceVariant	rs1870377
25589620	1562	1571	rs1870377	SequenceVariant	rs1870377
25589620	1666	1675	mucositis	DiseaseOrPhenotypicFeature	D052016
25589620	1772	1781	mucositis	DiseaseOrPhenotypicFeature	D052016
25589620	1807	1813	rs1695	SequenceVariant	rs1695
25589620	1835	1843	patients	OrganismTaxon	9606
25589620	1849	1862	rectal cancer	DiseaseOrPhenotypicFeature	D012004
25589620	1890	1896	rs4073	SequenceVariant	rs4073
25589620	1901	1910	rs1870377	SequenceVariant	rs1870377
25589620	1951	1959	toxicity	DiseaseOrPhenotypicFeature	D064420
25589620	1978	1982	5-FU	ChemicalEntity	D005472
25589620	Association	rs4073	D005472	Novel
25589620	Association	rs1695	D012004	Novel
25589620	Positive_Correlation	rs1870377	D052016	Novel
25589620	Association	rs1870377	D005472	Novel
25589620	Association	3791	D052016	Novel
25589620	Association	3791	D005472	No
25589620	Association	3576	D005472	No
25589620	Association	D012004	2950	Novel
25589620	Negative_Correlation	D005472	D012004	No